- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Alagille syndrome (ALGS)
- Meeting Date: July 2026
Odevixibat – July 2026
- Capsule 200 micrograms
- Capsule 400 micrograms
- Capsule 600 micrograms
- Capsule 1200 micrograms
Public Summary Documents
Last updated
13 November 2026
